GlassScriptPhysician profile
Opkar S Chawla
NPI 1871548776
$13,360.09
in general payments reported to CMS, 2019-2025
54 companies · $1,539 in 2025
The $1,539 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,433 · 2020: $2,090 · 2021: $1,565 · 2022: $1,710 · 2023: $2,138 · 2024: $1,885 · 2025: $1,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,562.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,000.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,759.62 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Lilly USA, LLC | $1,125.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,033.75 | 2020-2025 | |
| Amgen INC. | $890.64 | 2019-2025 | Evenity, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $799.61 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $563.44 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $468.46 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $345.78 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $305.79 | 2022-2024 | Verquvo, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.06 | 2019-2025 | |
| Abbvie INC. | $270.16 | 2021-2025 | Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $265.83 | 2019-2022 | |
| Allergan, INC. | $262.96 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $231.74 | 2024-2025 | Gemtesa, Myfembree |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $226.04 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $198.71 | 2023-2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $195.70 | 2024-2025 | Dupixent |
| Astellas Pharma US INC | $190.14 | 2020-2025 | Veozah |
| Glaxosmithkline, LLC. | $170.04 | 2020-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $167.42 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $159.75 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $156.72 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $155.02 | 2020 | |
| Idorsia Pharmaceuticals US INC | $151.70 | 2023-2024 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $111.82 | 2021-2025 | Zoryve, Livalo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.71 | 2021-2022 | |
| Intra-Sana Laboratories | $63.37 | 2023-2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Medtronic Minimed, INC. | $56.74 | 2020 | |
| Alnylam Pharmaceuticals INC. | $44.44 | 2021 | |
| Medtronic, INC. | $39.54 | 2021 | |
| Dynavax Technologies Corporation | $39.26 | 2022-2025 | Heplisav-B |
| Boston Scientific Corporation | $39.03 | 2024 | Varithena Administration Pack |
| Scilex Pharmaceuticals INC. | $38.04 | 2020-2021 | |
| Corcept Therapeutics | $37.22 | 2025 | Korlym |
| Dexcom, INC. | $36.98 | 2022-2024 | Dexcom G6 Transmitter |
| Bausch Health US, LLC | $35.75 | 2021-2024 | Aplenzin |
| Mayne Pharma Commercial LLC | $31.03 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $30.87 | 2019-2021 | |
| Eisai INC. | $26.88 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $23.16 | 2025 | Pyrukynd |
| Philips North America LLC | $23.11 | 2024 | (Ck7) Extended Holter |
| Hologic Sales and Service, LLC | $22.79 | 2023 | Thinprep 2000 Processor |
| Genzyme Corporation | $21.56 | 2024 | |
| Genentech USA, INC. | $20.52 | 2019 | |
| Evofem Biosciences, INC. | $20.46 | 2024 | |
| Acerus Pharmaceuticals Corporation | $19.91 | 2022 | |
| Rgh Enterprises LLC | $17.78 | 2025 | |
| Phadia US INC. | $17.40 | 2025 | Immunocap |
| Agile Therapeutics, INC. | $17.20 | 2023 | Twirla |
| Ultragenyx Pharmaceutical INC. | $16.97 | 2022 | |
| Seqirus USA INC | $16.77 | 2022 | |
| Therapeuticsmd, INC. | $16.00 | 2019 | |
| Esperion Therapeutics, INC. | $14.37 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Opkar Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.